Elagolix, Linzagolix, and Relugolix, as oral gonadotropin-releasing hormone antagonists, have emerged as promising treatments for endometriosis-associated pain.
Endometrial Cancer Treatment Market Forecast to grow USD 53.7 Billion by 2035 at a CAGR of 5.3 % | FMI Analysis industrytoday.co.uk
Endometriosis‑associated infertility is considered to be linked to cellular senescence. The present study assessed whether rapamycin, a senescence inhibitor, ameliorates endometriosis‑associated infertility by upregulating peroxisome proliferator‑activated receptor α (PPARα) and …
Endometriosis in adolescents presents unique diagnostic and management challenges compared to its manifestation in adult women. The symptoms can vary significantly among individuals, often resulting in a substantial delay in …
Human infertility represents a multifaceted condition, with oxidative stress (OS) and microRNAs (miRNAs) emerging as key contributors to its pathophysiology. This comprehensive review explores the complex interplay between reactive oxygen …
Endometriosis (EMS) is an estrogen-dependent disorder that affects about 10% of reproductive-age women. EMS affects female neuroendocrine and reproductive functions, greatly compromising female reproductive health and quality of life. However, …
To assess the impact of laparoscopic treatment of endometriosis on pregnancy outcomes in women with infertility, performed either before or after failed fertility enhancement technology (FET). Secondary aims included evaluating …
Kissei Pharmaceutical’s Promising Phase III Study on Endometriosis Treatment MSN
Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment MSN
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study MSN